Filana Therapeutics, Inc. Market Cap ($28.71 Million)
Market Cap & Net Worth: Filana Therapeutics, Inc. (FLNA)
Filana Therapeutics, Inc. market cap. Filana Therapeutics, Inc. (NASDAQ:FLNA) has a market capitalization of $28.71 Million ($28.71 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23742 globally and #5157 in its home market, demonstrating a -2.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Filana Therapeutics, Inc.'s stock price $0.59 by its total outstanding shares 48307896 (48.31 Million). Also see FLNA cash flow conversion for how efficiently the company converts equity into cash flow.
Filana Therapeutics, Inc. Market Cap History (2026–2026)
Filana Therapeutics, Inc. market cap history from 2026 to 2026. Data shows growth from $28.71 Million to $28.71 Million (0.00% CAGR). Check today's stock price for Filana Therapeutics, Inc. for real-time trading data and today's change.
Filana Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Filana Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Filana Therapeutics, Inc. net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of FLNA by Market Capitalization
Companies near Filana Therapeutics, Inc. in the global market cap rankings as of November 5, 2026. Also see FLNA total asset value for a full breakdown of the balance sheet.
Key companies related to Filana Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Filana Therapeutics, Inc. (2026–2026)
Market capitalization of Filana Therapeutics, Inc. from 2026 to today. Between 2026 and today, Filana Therapeutics, Inc.'s market cap moved from $28.71 Million to $ 28.71 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $28.71 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Filana Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.71 Million USD |
| MoneyControl | $28.71 Million USD |
| MarketWatch | $28.71 Million USD |
| marketcap.company | $28.71 Million USD |
| Reuters | $28.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more